LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | XL147 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6164 | 5752 | 1.0717 | 1.1212 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5779 | 5418 | 1.0666 | 1.1217 |
| SK-BR-3 | Saracatinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5777 | 5418 | 1.0665 | 1.1220 |
| SK-BR-3 | Enzastaurin | 10 | uM | LJP5 | 72 | hr | 2543 | 6171 | 5752 | 1.0728 | 1.1228 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6180 | 5752 | 1.0744 | 1.1255 |
| BT-20 | PD173074 | 1.11 | uM | LJP6 | 72 | hr | 1334 | 4322 | 3925 | 1.1010 | 1.1265 |
| SK-BR-3 | SB590885 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 6185 | 5752 | 1.0752 | 1.1271 |
| Hs 578T | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 765 | 3572 | 3148 | 1.1346 | 1.1276 |
| MCF7 | Celastrol | 0.04 | uM | LJP6 | 72 | hr | 1389 | 6120 | 5445 | 1.1282 | 1.1277 |
| BT-20 | HG-6-64-01 | 0.04 | uM | LJP6 | 72 | hr | 1334 | 4333 | 3925 | 1.1040 | 1.1313 |
| SK-BR-3 | Withaferin A | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5809 | 5418 | 1.0736 | 1.1383 |
| SK-BR-3 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5818 | 5418 | 1.0746 | 1.1384 |
| SK-BR-3 | SB590885 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 6223 | 5752 | 1.0820 | 1.1385 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 6233 | 5752 | 1.0837 | 1.1413 |
| MCF7 | PD173074 | 0.04 | uM | LJP6 | 72 | hr | 1389 | 6234 | 5445 | 1.1449 | 1.1423 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6242 | 5752 | 1.0853 | 1.1439 |
| MCF7 | Imatinib | 0.12 | uM | LJP6 | 72 | hr | 1389 | 6237 | 5445 | 1.1474 | 1.1453 |
| SK-BR-3 | WH-4-025 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6253 | 5752 | 1.0871 | 1.1469 |
| SK-BR-3 | SB590885 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 6254 | 5752 | 1.0872 | 1.1472 |
| SK-BR-3 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6256 | 5752 | 1.0876 | 1.1478 |
| Hs 578T | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 765 | 3587 | 3101 | 1.1563 | 1.1491 |
| Hs 578T | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 765 | 3596 | 3101 | 1.1593 | 1.1519 |
| SK-BR-3 | SB590885 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6271 | 5752 | 1.0903 | 1.1524 |
| BT-20 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 1334 | 4411 | 3925 | 1.1235 | 1.1545 |
| BT-20 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 1334 | 4437 | 3925 | 1.1302 | 1.1624 |